Cyclerion Therapeutics, Inc. (CYCN) Stock Price & Analysis
Cyclerion Therapeutics, Inc. (CYCN) fell 0.33% to USD 3 as of June 10, 2026 at 02:04 UTC, according to Nexqual real-time market data.
CYCN last closed at USD 3.01; the session ranged USD 2.98–3.1 on volume of 22,999 shares. Market capitalization is $12.99M, with a 52-week range of USD 1.03–8.48 (NCM). Source: Nexqual, June 10, 2026 at 02:04 UTC.
Key Statistics (as of June 10, 2026 at 02:04 UTC)
| Price | USD 3 |
|---|---|
| Change | ▼ 0.33% (down) |
| Previous Close | USD 3.01 |
| Open | USD 3.01 |
| Day Range | USD 2.98 – 3.1 |
| 52-Week Range | USD 1.03 – 8.48 |
| Volume | 22,999 shares |
| Market Cap | $12.99M |
| Exchange | NCM |
Technical Analysis (CYCN)
Nexqual's technical model rates CYCN "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.77 (neutral) |
| vs SMA50 | Below (USD 3.18) |
| MACD | -0 (negative) |
Analyst Ratings (CYCN)
Wall Street analysts rate CYCN "None" based on 1 analysts, with a mean price target of USD 8 (range USD 8–8), per Nexqual as of June 10, 2026 at 02:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 8 |
| High Target | USD 8 |
| Low Target | USD 8 |
Earnings (CYCN)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.19 vs est -0.38 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:04 UTC.
Financials & Fundamentals (CYCN)
| Total Revenue | $1.99M |
|---|---|
| Gross Margin | +17.06% |
| Operating Margin | -337.43% |
| Profit Margin | -264.73% |
| ROE | -67.77% |
| Current Ratio | 1.8 |
| Total Cash | $2.82M |
| Total Debt | $0 |
| Free Cash Flow | $-2.65M |
Source: Nexqual, June 10, 2026 at 02:04 UTC.
Financial Health Score (CYCN)
Nexqual rates Cyclerion Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -68%, ROA -45.8% |
Ownership (CYCN)
| Insider Ownership | +24.56% |
|---|---|
| Institutional Ownership | +4.17% |
| Shares Outstanding | 4.33M |
| Float | 3.49M |
| Short % of Float | +0.68% |
Source: Nexqual, June 10, 2026 at 02:04 UTC.
Leadership (CYCN)
Cyclerion Therapeutics, Inc. is led by Regina M. Graul (age 47), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:04 UTC.
| CEO, President & Director | Regina M. Graul (age 47) |
|---|---|
| Chief Financial Officer | Rhonda M. Chicko (age 58) |
Major Backers & Investors (CYCN)
Notable institutional backers of Cyclerion Therapeutics, Inc. include Fidelity, Citadel, Kovack Advisors, Inc., according to Nexqual as of June 10, 2026 at 02:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 9.75% |
| Citadel | 0.42% |
| Kovack Advisors, Inc. | 0.23% |
| FMR, LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.95% |
| Vanguard Group | 0.91% |
| BlackRock | 0.39% |
Source: Nexqual, June 10, 2026 at 02:04 UTC.
From Cyclerion Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.
- The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.
- It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| ELOX | Eloxx Pharmaceuticals, Inc. Common Stock | USD 11.01 | ▲ 77.58% |
| PRFX | PRF Technologies Ltd. | USD 1.42 | ▼ 10.69% |
| EDSA | Edesa Biotech, Inc. | USD 4.94 | ▼ 9.52% |
| APRE | Aprea Therapeutics, Inc. | USD 0.74 | ▼ 0.34% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:04 UTC. This page is informational and not investment advice.